Prognostic Value of Mdm2, p53 and p16 in Patients with Astrocytomas

By Ranuncolo Stella   Varela Mirta   Morandi Ana   Lastiri José   Christiansen Silvia   Bal de Kier Joffé Elisa   Pallotta María   Puricelli Lydia  

Journal of Neuro-Oncology, Vol. 68, Iss. 2, 2004-06 ,pp. : 113-121

Springer Publishing Company

Access to resources Recommend Favorite

The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies

By Cox David   Deer Dwayne   Guo Qun   Tworoger Shelley   Hankinson Susan   Hunter David   Vivo Immaculata  

Cancer Causes and Control, Vol. 18, Iss. 6, 2007-08 ,pp. : 621-625

Springer Publishing Company

Access to resources Recommend Favorite

MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer

By                            

Oncology Reports, Vol. 27, Iss. 3, 2012-01 ,pp. : 673-677

Spandidos Publications

Access to resources Recommend Favorite

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation

By Katz Matthew  

Annals of Surgical Oncology, Vol. 17, Iss. 7, 2010-07 ,pp. : 1794-1801

Springer Publishing Company

Access to resources Recommend Favorite

Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy

By Huang Zhao-Hui   Hua Dong   Du Xiang  

Cancer Chemotherapy and Pharmacology, Vol. 64, Iss. 5, 2009-10 ,pp. : 1001-1007

Springer Publishing Company

Access to resources Recommend Favorite